1[6]Masuda N, Ohya S. Cross-resistance to meropenem cephems and quinolones in Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1992, 36(8): 1847
3Bingen EH, Desjardins P, Arlet G,et al. Molecular epidemiology of plasmid spread among extended broad-spectrum-β-lac-tamase-producing Klebsiella pneumoniae isolates in a pediatric hospital[J]. J Clin Microbiol, 1993, 31: 179.
4National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests approved standard [S]. Seventh edition. NCCLS M100-S10(M7), January 2000.
5Patterson JE, Hardin TC, Kelly CA, et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae[J]. Infect Control Hosp Epidemiol, 2000, 21: 455-458.
6Schiappa DA, Hayden MK, Matushek MG, et al. Cef-tazidime-resistant Klebsiella pneumoniae and Escherichia coli blood stream infection: a case-control and molecular epidemiologic investigation[J]. J Infect Dis, 1996, 174: 529-536.
7Abudu L, Blair I, Fraise A, et al. Methicillin-resistant Staphylococcus aureus (MRSA): a community-based prevalence survey. Epidemiol Infect,2001 ,126:351-356.
8Pan A, Catenazzi P, Ferrari L. Evaluation of the efficacy of a program to control nosocomial spread of methicillin-resistant Staphylococcus aureus. Infez Med , 2001 ,9 :163-169.
9Daschner F, Schumpelick V. Schiedel L. MRSA as a challenge to clinical organization. Chirurg ,2002 ,73:924-929.
10Bartley J . First case of VRSA identified in Michigan. Infect Control hospi Epidemiol ,2002,23:480.
